These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16303007)

  • 1. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
    Holdaas H; Fellström B; Cole E; Nyberg G; Olsson AG; Pedersen TR; Madsen S; Grönhagen-Riska C; Neumayer HH; Maes B; Ambühl P; Hartmann A; Staffler B; Jardine AG;
    Am J Transplant; 2005 Dec; 5(12):2929-36. PubMed ID: 16303007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
    Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
    Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.
    Holdaas H; Fellström B; Holme I; Nyberg G; Fauchald P; Jardine A; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Weinreich T; Olsson AG; Pedersen TR; Benghozi R; Hartmann A;
    J Cardiovasc Risk; 2001 Apr; 8(2):63-71. PubMed ID: 11324372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
    Holdaas H; Fellström B; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Solbu DO; Pedersen TR;
    Lancet; 2003 Jun; 361(9374):2024-31. PubMed ID: 12814712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.
    Robertsen I; Asberg A; Granseth T; Vethe NT; Akhlaghi F; Ghareeb M; Molden E; Reier-Nilsen M; Holdaas H; Midtvedt K
    Transplantation; 2014 Jun; 97(12):1266-71. PubMed ID: 24521776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial).
    Ostadal P; Alan D; Vejvoda J; Kukacka J; Macek M; Hajek P; Mates M; Kvapil M; Kettner J; Wiendl M; Aschermann O; Slaby J; Holm F; Telekes P; Horak D; Blasko P; Zemanek D; Veselka J; Cepova J
    Trials; 2010 May; 11():61. PubMed ID: 20500832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
    Fellström B; Abedini S; Holdaas H; Jardine AG; Staffler B; Gimpelewicz C;
    Clin Transplant; 2006; 20(6):732-9. PubMed ID: 17100723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment.
    Soveri I; Abedini S; Holdaas H; Jardine A; Eriksson N; Fellström B
    Clin Transplant; 2009; 23(6):914-20. PubMed ID: 19594771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study.
    Jardine AG; Holdaas H; Fellström B; Cole E; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Maes B; Ambühl P; Olsson AG; Holme I; Fauchald P; Gimpelwicz C; Pedersen TR;
    Am J Transplant; 2004 Jun; 4(6):988-95. PubMed ID: 15147434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
    Holdaas H; Fellström B; Jardine AG; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Logan JO; Staffler B; Gimpelewicz C;
    Nephrol Dial Transplant; 2005 May; 20(5):974-80. PubMed ID: 15784644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
    Fellström B; Holdaas H; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Logan JO; Pedersen TR;
    Kidney Int; 2004 Oct; 66(4):1549-55. PubMed ID: 15458450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of atorvastatin in heart transplant recipients.
    Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
    J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
    Olsson AG; Pauciullo P; Soska V; Luley C; Pieters RE; Broda G; Palacios B;
    Clin Ther; 2001 Jan; 23(1):45-61. PubMed ID: 11219479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
    Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
    Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of fluvastatin extended-release tablets in Chinese patients with hyperlipidemia: a multi-center, randomized, double-blind, double dummy, active-controlled, parallel-group study].
    Zhao S; Wang F; Yang K; Hao Y; Li G; Yang M; Yang Z
    Zhonghua Nei Ke Za Zhi; 2014 Jun; 53(6):455-9. PubMed ID: 25146513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.